Evidence map›Paper›PMID 25104936›Full record

ReviewFrontiers in pharmacology2014

Discovering novel neuroactive drugs through high-throughput behavior-based chemical screening in the zebrafish.

Giancarlo Bruni, Parth Lakhani, David Kokel

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in pharmacology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed
5.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 84 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Early Life Exposure to ΔCannabis and cannabinoid research · 2025
    Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Sensory-Motor Perturbations in Larval Zebrafish (International journal of molecular sciences · 2022
    Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. High-throughput Measurement of Gut Transit Time Using Larval Zebrafish.Journal of visualized experiments : JoVE · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Giancarlo BruniCardiovascular Research Center, Massachusetts General Hospital and Harvard Medical School Charlestown, MA, USA.
Parth LakhaniCardiovascular Research Center, Massachusetts General Hospital and Harvard Medical School Charlestown, MA, USA.
David KokelCardiovascular Research Center, Massachusetts General Hospital and Harvard Medical School Charlestown, MA, USA.
Massachusetts General Hospital · US

Funding

Behavior-based chemical screening for GABAergic and startle modifying drugsR01AA022583 · NIAAA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KOKEL, DAVID · 2013 to 2017
$1.6M
NIAAA NIH HHS R01 AA022583
6 · The paper itself

Abstract

Most neuroactive drugs were discovered through unexpected behavioral observations. Systematic behavioral screening is inefficient in most model organisms. But, automated technologies are enabling a new phase of discovery-based research in central nervous system (CNS) pharmacology. Researchers are using large-scale behavior-based chemical screens in zebrafish to discover compounds with new structures, targets, and functions. These compounds are powerful tools for understanding CNS signaling pathways. Substantial differences between human and zebrafish biology will make it difficult to translate these discoveries to clinical medicine. However, given the molecular genetic similarities between humans and zebrafish, it is likely that some of these compounds will have translational utility. We predict that the greatest new successes in CNS drug discovery will leverage many model systems, including in vitro assays, cells, rodents, and zebrafish.

Indexed as

antipsychoticsbehavior-based drug discoveryphenomicsscreeningzebrafish

Identifiers

PMID25104936
PMCPMC4109429
OpenAlexW2124403318

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.